Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis

Zheng,Wanwei; Luo,Zhongguang; Zhang,Jun; Min,Pei; Li,Wenshuai; Xu,Diannan; Zhang,Ziqiang; Xiong,Panpan; Liang,Hong; Liu,Jie

doi:10.3892/mmr.2017.6305

Neural precursor cell expressed, developmentally downregulated 8‑activating enzyme inhibitor MLN4924 sensitizes colorectal cancer cells to oxaliplatin by inducing DNA damage, G2 cell cycle arrest and apoptosis

Authors:
- Wanwei Zheng
- Zhongguang Luo
- Jun Zhang
- Pei Min
- Wenshuai Li
- Diannan Xu
- Ziqiang Zhang
- Panpan Xiong
- Hong Liang
- Jie Liu
View Affiliations

Affiliations: Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Digestive Diseases, Southeast Hospital, Xiamen University, Zhangzhou, Fujian 363000, P.R. China, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China, Department of Digestive Diseases, East Hospital, Tongji University, Shanghai 200120, P.R. China
Published online on: March 9, 2017 https://doi.org/10.3892/mmr.2017.6305
Pages: 2795-2801

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin-based chemotherapy is a primary treatment for patients with metastatic colorectal cancer (CRC); however, its efficacy is limited. Therefore, novel therapeutic agents are urgently required. MLN4924 is a first‑in‑class inhibitor of neural precursor cell expressed, developmentally downregulated 8 (NEDD8)‑activating enzyme E1, and has entered various phase‑I/II clinical trials for cancer therapy due to its significant anticancer efficacy. The aim of the present study was to examine the synergistic effect and underlying mechanisms of MLN4924 and oxaliplatin combined treatment for CRC. It was demonstrated that MLN4924 treatment induced the DNA damage response (DDR) by inactivating cullin‑ring ubiquitin ligases, subsequently leading to cell cycle disturbance and apoptosis in CRC cells. MLN4924 treatment increased the oxaliplatin‑induced DDR, G2 cell cycle arrest and apoptosis. Protein expression levels of phosphorylated checkpoint kinase 2 (p‑CHK2), p21 and p53, which are well‑known functional proteins involved in G2 cell cycle arrest, were assessed. p‑CHK2 protein expression levels were increased following combined treatment with MLN4924 and oxaliplatin, whereas p21/p53 protein expression levels were not. In conclusion, MLN4924 treatment may sensitize CRC cells to oxaliplatin treatment by inducing the DDR and increasing protein expression levels of p‑CHK2, leading to G2 cell cycle arrest and apoptosis. Therefore, combined MLN4924 and oxaliplatin‑based chemotherapy may be a potential therapeutic strategy for the treatment of CRC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, Kim K and Shim YM: Pulmonary resection for metastases from colorectal cancer: Prognostic factors and survival. Int J Colorectal Dis. 22:699–704. 2007. View Article : Google Scholar : PubMed/NCBI
3	Yoo PS, Lopez-Soler RI, Longo WE and Cha CH: Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer. 6:202–207. 2006. View Article : Google Scholar : PubMed/NCBI
4	Mowaka S, Ziehe M, Mohamed D, Hochkirch U, Thomale J and Linscheid MW: Structures of oxaliplatin-oligonucleotide adducts from DNA. J Mass Spectrom. 47:1282–1293. 2012. View Article : Google Scholar : PubMed/NCBI
5	Virag P, Perde-Schrepler M, Fischer-Fodor E, Tatomir C, Dorneanu SA, Cernea VI and Irimie A: Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines. Anticancer Drugs. 23:1032–1038. 2012. View Article : Google Scholar : PubMed/NCBI
6	Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008. View Article : Google Scholar : PubMed/NCBI
7	Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
8	Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, et al: Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature. 416:703–709. 2002. View Article : Google Scholar : PubMed/NCBI
10	Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
11	Petroski MD and Deshaies RJ: Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol. 6:9–20. 2005. View Article : Google Scholar : PubMed/NCBI
12	Petroski MD: Mechanism-based neddylation inhibitor. Chem Biol. 17:6–8. 2010. View Article : Google Scholar : PubMed/NCBI
13	Soucy TA, Dick LR, Smith PG, Milhollen MA and Brownell JE: The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer. 1:708–716. 2010. View Article : Google Scholar : PubMed/NCBI
14	Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, et al: Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: The NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell. 37:102–111. 2010. View Article : Google Scholar : PubMed/NCBI
15	Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K and Lightcap ES: Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics. 10:M111.0091832011. View Article : Google Scholar : PubMed/NCBI
16	Bennett EJ, Rush J, Gygi SP and Harper JW: Dynamics of cullin-RING ubiquitin ligase network revealed by systematic quantitative proteomics. Cell. 143:951–965. 2010. View Article : Google Scholar : PubMed/NCBI
17	Milhollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, et al: MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: Rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood. 116:1515–1523. 2010. View Article : Google Scholar : PubMed/NCBI
18	Jia L, Li H and Sun Y: Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia. 13:561–569. 2011. View Article : Google Scholar : PubMed/NCBI
19	Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, et al: Inhibition of NEDD8-activating enzyme: A novel approach for the treatment of acute myeloid leukemia. Blood. 115:3796–3800. 2010. View Article : Google Scholar : PubMed/NCBI
20	Lin JJ, Milhollen MA, Smith PG, Narayanan U and Dutta A: NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res. 70:10310–10320. 2010. View Article : Google Scholar : PubMed/NCBI
21	Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG and Amidon B: Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res. 71:3042–3051. 2011. View Article : Google Scholar : PubMed/NCBI
22	Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, Smith PG, Morgan MA and Sun Y: Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res. 72:282–293. 2012. View Article : Google Scholar : PubMed/NCBI
23	Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI
24	Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M and Juniewicz PE: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol. 58:920–927. 2000.PubMed/NCBI
25	Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A and Carew JS: Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res. 19:3577–3590. 2013. View Article : Google Scholar : PubMed/NCBI
26	Rogakou EP, Nieves-Neira W, Boon C, Pommier Y and Bonner WM: Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem. 275:9390–9395. 2000. View Article : Google Scholar : PubMed/NCBI
27	Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K and Elledge SJ: Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA. 97:10389–10394. 2000. View Article : Google Scholar : PubMed/NCBI
28	Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science. 282:1497–1501. 1998. View Article : Google Scholar : PubMed/NCBI
29	Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ and Mak TW: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science. 287:1824–1827. 2000. View Article : Google Scholar : PubMed/NCBI
30	Rainey MD, Black EJ, Zachos G and Gillespie DA: Chk2 is required for optimal mitotic delay in response to irradiation-induced DNA damage incurred in G2 phase. Oncogene. 27:896–906. 2008. View Article : Google Scholar : PubMed/NCBI
31	Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG and D'Andrea AD: Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res. 10:369–377. 2012. View Article : Google Scholar : PubMed/NCBI
32	Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56:4881–4886. 1996.PubMed/NCBI